Essential ESiOR: 5 presentations at ISPOR

It is time for celebration. ESiOR will participate in International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress in Vienna for the tenth time. ISPOR is a must for everyone interested in pharmacoeconomics and outcomes research. Let’s meet in the congress!

Ongoing regional government reform and social welfare and healthcare (SOTE) reform will increase the importance of Health Services Research (HSR) in Finland. The trend has recently also been visible in ISPOR for HSR and its subarea, Real World Evidence (RWE). Cooperation between various stakeholders has expanded, as well.

Majority of ESiOR’s presentations this year deals with HSR, effectiveness assessment, and benchmarking. Contents include new tools and methods developed by ESiOR, such as setting reasonable effectiveness goals, assessing benefit potential, estimating remaining medical needs, and appropriate risk assessment. Additionally, ESiOR’s register analysis on multiple sclerosis was already nominated for ISPOR poster award.

ESiOR presentations:PND15. Disease Modifying Treatment (DMT) is associated with lower hazard for death among Multiple Sclerosis (MS) patients: Survival analysis based on 30 years incident MS cohort.

PRM191. Watch out for Berkson’s Bias (BB)! Setting Health-Related Quality of Life (HRQoL) treatment targets with Matching-Adjusted Indirect Comparison (MAIC) in order to predict Matched General Population Control (MGPC) targets, assess Potential to Benefit (PTB) and reveal Unmet Medical Need (UMN).

PHP184. Health-Related Quality of Life (HRQoL) based on preferences from 14 countries in Primary Health Care Setting (PHCS).

PHP226. Comorbidity-based EQ-5D scores of primary care patients in Finland, their potential to benefit and unmet medical need.

PHP253. ICPC-2 episode-based health-related quality of life and three months’ effectiveness in three Finnish primary health care settings.

Contact information: Erkki Soini.